% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{John:275941,
      author       = {L. John$^*$ and K. Miah$^*$ and A. Benner$^*$ and E. K. Mai
                      and K. Kriegsmann and M. Hundemer and D. Kaudewitz and C.
                      Müller-Tidow and K. Jordan and H. Goldschmidt and M. S.
                      Raab$^*$ and N. Giesen},
      title        = {{I}mpact of novel agent therapies on immune cell subsets
                      and infectious complications in patients with
                      relapsed/refractory multiple myeloma.},
      journal      = {Frontiers in oncology},
      volume       = {13},
      issn         = {2234-943X},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2023-00929},
      pages        = {1078725},
      year         = {2023},
      note         = {#EA:A360#},
      abstract     = {Infections are a leading cause of morbidity and mortality
                      in patients with multiple myeloma (MM).To examine the
                      effects of modern second-generation novel agent therapy on
                      immune cell subsets, in particular CD4+-T-cells, and
                      infectious complications in patients with
                      relapsed/refractory MM (RRMM), we conducted a prospective
                      cohort study in 112 RRMM patients.Substantially decreased
                      CD4+-T-cells <200/µl before initiation of relapse therapy
                      were detected in $27.7\%$ of patients and were associated
                      with a higher number of previous lines of therapy. Relapse
                      therapy with carfilzomib or pomalidomide showed a
                      significant further decrease of CD4+-T-cells. All novel
                      agents led to a significant decrease of B-cell counts.
                      Overall, infections were frequent with $21.3\%$ of patients
                      requiring antibacterial therapy within the first 3 months of
                      relapse therapy, $5.6\%$ requiring hospitalization. However,
                      in the setting of standard antimicrobial prophylaxis in RRMM
                      patients with very low CD4+-T-cells, no significant
                      association of CD4+T-cell count and an increased risk of
                      infection could be detected.Our findings imply that reduced
                      CD4+-T-cell numbers and infections are common in patients
                      with RRMM. We also demonstrate an association with the
                      number of previous therapies and certain substances
                      suggesting an increased need for personalized prophylaxis
                      strategies for opportunistic infections in this patient
                      cohort.},
      keywords     = {CD4+-T-cells (Other) / immune cell subsets (Other) /
                      infections (Other) / novel agents (Other) / relapsed
                      refractory multiple myeloma (Other)},
      cin          = {A360 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)A360-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37152008},
      pmc          = {pmc:PMC10160457},
      doi          = {10.3389/fonc.2023.1078725},
      url          = {https://inrepo02.dkfz.de/record/275941},
}